Rowland, Andrew - Flinders University - Department of Clinical Pharmacology

研究领域

Drug and chemical metabolism. In vitro and in silico physiological based pharmacokinetic modelling.

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Dawson, J., Dedigama, M., Elliot, D.J., Sorich, M., Mangoni, A.A. and Rowland, A. (2016). Prolonged induction of warfarin metabolism and a paradoxical INR response in a mitral valve replacement patient receiving rifampicin for infective endocarditis. Biomedical Research and Clinical Practice, 1(2) pp. 62-65. [10.15761/BRCP.1000112] Mangoni, A.A., Woodman, R.J., Kichenadasse, G., Rowland, A. and Sorich, M. (2016). Anti-VEGF-induced hypertension and cancer outcomes: translating research into clinical practice. Expert Review of Precision Medicine and Drug Development, 1(2) pp. 12 5-127. [10.1080/23808993.2016.1155963] Polasek, T.M., Rowland, A., Wiese, M.D. and Sorich, M. (2015). Pharmacists in Australian general practice: an opportunity for expertise in precision medicine. Therapeutic Advances in Drug Safety, 6(5) pp. 186-188. [10.1177/2042098615599947] [Scopus] Rowland, A., Dias, M.M., Wiese, M.D., Kichenadasse, G., McKinnon, R.A., Karapetis, C.S., et al. (2015). Reply: Comment on ‘Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer’ British Journal of Cancer, [10.1038/bjc.2015.325] [Scopus] Sorich, M., Rowland, A. and Wiese, M. (2014). Pharmacogenomic substudies of randomized controlled trials: consideration of safety outcomes. Therapeutic Advances in Drug Safety, 5(2) pp. 62-66. [10.1177/2042098613520030] [Scopus]